how long do side effects of glp 1 last A monthly GLP-1 dose could cut the number shots patients take each year from 52 to 12. from the drug — mainly gastrointestinal symptoms — were similar to or GLP-1 Side Effects Have a

CJC-1295 is not FDA approved for general medical use

Rhonda Patrick: And they're getting more vitamin D

Retrieved 2026-01-05.

fast Download PDF Now- 20262029 pipeline snapshot: Novo Nordisk CagriSema (GLP-1 + amylin) Filing 2026 Lilly Orforglipron (oral GLP-1) + Retatrutide (triple agonist) Launch window 20262027 Amgen Maritide (GLP-1 + GIP) 20272028 target BI / Zealand Survodutide (GLP-1 + glucagon) 2027 Altimmune Pemvidutide (GLP-1 + glucagon) 2027 Roche CT-388 / Petrelintide possible 2029 And one notable miss: Pfizer Danuglipron discontinued Clear trend: Single GLP-1 dual triple agonists Competition is shifting from: Who has a GLP-1? to Who has the most effective combination biology? Execution risk is still real but the bar for efficacy is moving quickly